These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17077140)

  • 21. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
    Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
    Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
    Lu M; Xia L; Li Y; Wang X; Hoffman R
    Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.
    Ho JM; Beattie BK; Squire JA; Frank DA; Barber DL
    Blood; 1999 Jun; 93(12):4354-64. PubMed ID: 10361134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
    Tong W; Zhang J; Lodish HF
    Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.
    Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB
    Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
    Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
    Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate.
    Grover A; Mancini E; Moore S; Mead AJ; Atkinson D; Rasmussen KD; O'Carroll D; Jacobsen SE; Nerlov C
    J Exp Med; 2014 Feb; 211(2):181-8. PubMed ID: 24493804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
    Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
    Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.
    Anand S; Stedham F; Gudgin E; Campbell P; Beer P; Green AR; Huntly BJ
    Blood; 2011 Aug; 118(6):1610-21. PubMed ID: 21653937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera.
    Perna F; Gurvich N; Hoya-Arias R; Abdel-Wahab O; Levine RL; Asai T; Voza F; Menendez S; Wang L; Liu F; Zhao X; Nimer SD
    Blood; 2010 Oct; 116(15):2812-21. PubMed ID: 20585043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
    Miura O; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N
    Blood; 1994 Sep; 84(5):1501-7. PubMed ID: 8068943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK2, the JAK2 V617F mutant and cytokine receptors.
    Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
    Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.
    Wang X; Prakash S; Lu M; Tripodi J; Ye F; Najfeld V; Li Y; Schwartz M; Weinberg R; Roda P; Orazi A; Hoffman R
    J Clin Invest; 2012 Nov; 122(11):3888-99. PubMed ID: 23023702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.
    Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
    Wang X; Zhang W; Tripodi J; Lu M; Xu M; Najfeld V; Li Y; Hoffman R
    Blood; 2010 Dec; 116(26):5972-82. PubMed ID: 20858855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.